AWM
AXSM icon

Adams Wealth Management’s Axsome Therapeutics AXSM Stock Holding History

Adams Wealth Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,169
Closed -$389K – 152
2025
Q4 		$389K Hold
2,169
– – 0.08% 109
2025
Q3 		$259K Hold
2,169
– – 0.06% 152
2025
Q2 		$225K Hold
2,169
– – 0.04% 156
2025
Q1 		$251K Buy
+2,169
New +$247K 0.05% 116

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adams Wealth Management's AXSM Position: Q1 2026 in Review

Adams Wealth Management sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 2,169 shares — an estimated $389K sold.

Adams Wealth Management first reported a position in AXSM in Q1 2025 and held it in 4 quarters. The position peaked at $389K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Adams Wealth Management reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Adams Wealth Management sold 2,169 Axsome Therapeutics shares in Q1 2026, an estimated $389K.
  • Adams Wealth Management first reported a position in Axsome Therapeutics in Q1 2025 and held it in 4 quarters.
  • Adams Wealth Management's Axsome Therapeutics position peaked at $389K in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Adams Wealth Management's 13F filing for Q1 2026, filed 12 May 2026.